DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lzxd54/latestage) has announced the addition of the "Late-Stage Four-FCritical Care Therapeutics in Major Developed Markets to 2020 - New andactor PCCs and Recombinant Products to Drive Market" report to their offering.
The critical care market in the eight major developed markets (the US, UK, France, Germany, Italy, Spain, Japan and Canada) was worth an estimated $1.8 billion in 2013 and is expected to grow to $2.5 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 4.7%. The majority of this revenue was due to albumin sales which amounted to $1.1 billion in 2013 and are expected to grow to $1.6 billion by 2020. In terms of markets, the US held the largest share with 41% of the total critical care market in 2013 and is projected to grow at the highest rate of any market at 7.5% during the 2013-2020 period.
Albumin was used to treat the highest share of the critical care treatment population across all eight markets with 2.2 million patients of a total of 2.4 million in 2013. Expectedly, the highest share of these patients was in the US, a total of 46% in 2013. A further 39.3% of the 2013 treatment population were located in the top five countries of Europe, followed by Japan with 9.5% and rest from Canada. The treatment population in the US is estimated to grow at a CAGR of 0.9% until 2020 with highest growth expected in the number of patients treated with Prothrombin Complex Concentrate (PCC) which is expected to grow at a CAGR of 2%. Globally, the treatment population receiving Anti-Thrombin (AT) concentrates and PCCs is expected to be larger than any other category and will grow at a CAGR of 1.5% during the 2013-2020 period.
The projected high growth rate of revenues in the US market of 7.5% is mainly due the increased uptake of factor concentrates over older alternatives (such as Fresh-Frozen Plasma (FFP)), higher price inflation and the launch of new drugs such as Kcentra (PPC, human) and Tretten (Factor XIII concentrate, recombinant) in 2013. Kcentra is the first four-factor PCC in the US and Tretten is the first recombinant factor XIII concentrate. In the top five European critical care markets there have been no recent significant product launches and none are expected during the forecast period. These markets are therefore anticipated to grow slowly during the forecast period, the UK market will grow at a CAGR of 3.0%, followed by France at 2.5%, Germany and Spain will each grow at 2.3% and Italy at 2.0%.
Key Topics Covered:
1 Tables & Figures
- Albumin in Critical Care
- Anti-Thrombin III Concentrates in Critical Care
- Factor XIII Concentrates in Critical Care
- Fibrinogen Concentrates in Critical Care
- Prothrombin Complex Concentrate in Critical Care
3 Therapeutic Landscape
- Albumin Products
- Anti-Thrombin Concentrates
- Factor XIII Concentrates
- Fibrinogen Concentrates
- Prothrombin Complex Concentrates
4 Pipeline for Critical Care Market
- Overview of Pipeline
- Promising Pipeline Candidates
5 Critical Care Market Forecast to 2020
- Geographical Markets
- Drivers and Barriers
6 Deals and Strategic Consolidations
- Bain Capital
- CSL Behring
- Inspiration Biopharma
- Plasma Resources
- Sangamo BioSciences
- Shin Poong Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/lzxd54/latestage